What Bora Biologics does

Bora Biologics is a San Diego-headquartered contract development and manufacturing organization (CDMO) specializing in mammalian and microbial biologics, founded in 2011 as a subsidiary of Taiwan-based Tanvex BioPharma, Inc. The company provides end-to-end services spanning cell line development, upstream and downstream process development, analytical development, formulation development, GMP drug substance manufacturing, and tech transfer, with drug product fill-finish delivered through affiliate Bora Pharmaceuticals' 87,000 sf facility in Baltimore, MD. Its proprietary technology stack includes a CHO cell line platform achieving 4-6 g/L titers, an Allosteric Formulation Development Platform, and a Biophysical High Throughput Platform that uses advanced spectroscopic and biophysical instrumentation for rapid formulation screening. The company operates an FDA-registered facility in San Diego with newly validated 2,000L single-use bioreactor capacity (following a $30M expansion completed January 2026) and a TFDA-registered cGMP facility in Zhubei City, Taiwan, together totaling more than 175,000 sf of GMP and R&D space.

Bora Biologics employs 125 scientists and regulatory specialists (over 50% with advanced degrees) and has delivered 100+ cGMP batches across 50 biologic and biosimilar programs, including one commercial biosimilar approved in both the U.S. and Canada. Revenue is generated through project-based, fee-for-service CDMO contracts priced per engagement scope, typically structured as multi-year agreements with enterprise biopharma sponsors. The go-to-market model relies on direct enterprise sales, technical publications, case studies, and conference participation (BIO 2026, CDMO Live Europe), targeting mid-to-large biopharma and biotech sponsors needing late-stage and commercial-scale biologics manufacturing, particularly those seeking U.S.-based supply. Recent strategic activity — including the May 2026 acquisition of MacroGenics' GMP operations and the commercial-scale 2,000L validation — positions Bora as a scaling mid-market biologics CDMO with both clinical and commercial manufacturing capability across two regulatory jurisdictions.

Name

Bora Biologics

Legal name

Bora Biologics BioPharma, Inc.

Website

https://borabiologics.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

101–250 employees

Short description

Bora Biologics is a San Diego-based contract development and manufacturing organization (CDMO) specializing in mammalian and microbial biologics from cell line development through commercial GMP manufacturing and fill-finish services for biopharma sponsors.

Ownership category

akta.pro rank

Product category

Biologics Contract Manufacturing (CDMO)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Contract biologics manufacturing
• Mammalian cell culture
• Microbial fermentation
• Biologics process development
• Fill-finish services

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Contract Development and Manufacturing (CDMO) Services: Bora Biologics generates revenue through providing fee-for-service contract development and manufacturing services to biopharma sponsors. Services span the full product lifecycle from cell line development, process development, analytical development, GMP manufacturing (drug substance), through technology transfer. Revenue is project-based with custom scopes, timelines, and pricing negotiated per engagement. The company also transfers drug substances to its affiliate Bora Pharmaceuticals for fill-finish and drug product services, forming an integrated end-to-end CDMO offering.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels9 records

Core offering

Bora Biologics is a contract development and manufacturing organization (CDMO) that provides end-to-end biologics services spanning cell line development, mammalian and microbial process development, analytical and formulation development, GMP drug substance manufacturing, and fill-finish drug product services. The company operates FDA-registered facilities in San Diego, CA and TFDA-registered facilities in Zhubei City, Taiwan, serving biopharma sponsors from preclinical through commercial-scale production of monoclonal antibodies, bispecifics, ADCs, fusion proteins, enzymes, and biosimilars.

Product overview

Bora Biologics is a technology-driven Contract Development and Manufacturing Organization (CDMO) offering an integrated platform spanning development through commercialization. The core offering consists of Mammalian GMP Manufacturing and Microbial GMP Manufacturing, complemented by development service modules including Cell Line Development, Mammalian Process Development, Microbial Process Development, Analytical Development, Formulation & Drug Product Development, and Tech Transfer. Drug Product Services (fill-finish) are delivered through partnership with Bora Pharmaceuticals. The company specializes in late-stage execution and commercial-scale production of biologics including monoclonal antibodies, bispecifics, ADCs, fusion proteins, and enzymes at FDA-registered facilities in San Diego, CA and Zhubei City, Taiwan.

Differentiator

Problem solved

Functional benefit

Products and services

• Mammalian GMP Manufacturing Full-service mammalian cell culture manufacturing using single-use bioreactor technology (50L to 2,000L scale) with integrated upstream, downstream, and quality systems at the FDA-registered San Diego facility. Designed for biopharma sponsors requiring clinical-to-commercial scale GMP production.
• Microbial GMP Manufacturing Efficient microbial-derived biologics manufacturing using stainless steel fermentors (150L, 300L) and single-use fermentation technology for secreted and intracellular products, serving sponsors from pre-clinical through commercial scale.
• Drug Product Services Comprehensive fill-finish services including vials and pre-filled syringes, liquid and lyophilization, visual inspection, packaging, and serialization. Delivered through partnership with affiliate Bora Pharmaceuticals at the Baltimore, MD facility for clinical and commercial drug product manufacturing.
• Cell Line Development Robust cell line development using a proprietary CHO cell line platform with CRISPR/Cas9 gene editing, clone screening, and characterization to create high-yield, stable cell lines for biologics production.
• Mammalian Process Development Optimization of cell culture and downstream purification processes including high-throughput media screening, chromatography development, filtration process development, and scale-up to 2,000L batches for mammalian biologics production.
• Microbial Process Development Scalable fermentation development for E. coli and yeast systems, including high-yield fermentation optimization, downstream purification, and process scale-up from pre-clinical to commercial scale.
• Analytical Development Comprehensive analytical services including identity and purity testing, structural characterization, biological/functional characterization, microbiology testing, and analytical method validation for biologics.
• Formulation & Drug Product Development Drug product formulation development using a proprietary Allosteric Formulation Development Platform and Biophysical HT Platform for rapid pre-formulation screening, stability assessment, and excipient compatibility studies.
• Tech Transfer Technology transfer services ensuring smooth transition from development to manufacturing, including comprehensive assessment, cross-functional collaboration, and robust documentation practices; particularly used to transition Asia-based programs to U.S. commercial supply.

Quantifiable outcome

• 40% increase in mammalian process yield through process development optimization
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Partnerships

One partnership is on record.

• Bora PharmaceuticalscoreStrategic or Co-development PartnerBora Biologics transfers biologic drug substances to its affiliate Bora Pharmaceuticals for comprehensive drug product (fill-finish) services. Bora Pharmaceuticals operates an 87,000 sf cGMP drug product facility in Baltimore, MD. This partnership enables an end-to-end CDMO offering from drug substance to drug product under an integrated 'Power of One' single-agreement model. The collaboration provides clinical and commercial manufacturing capabilities for vials, pre-filled syringes, liquid and lyophilized products, with inspection, packaging, and serialization.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Thermo Fisher Scientific (Patheon / Brammer Bio): Through its pharma services segment, Thermo Fisher offers biologics CDMO capabilities including mammalian manufacturing and fill-finish. Competes with Bora across most service lines, with the advantage of integrated small-molecule, biologics, and clinical-trial-services capabilities.
• Lonza Biologics: Global CDMO leader offering mammalian and microbial biologics development and manufacturing across multiple sites in Switzerland, the U.S., and Asia. Competes directly with Bora across the full biologics CDMO value chain, with far larger scale and longer commercial track record.
• Samsung Biologics: One of the world's largest biologics CDMOs with 364,000L of total bioreactor capacity across multiple plants in Songdo, South Korea. Directly competes with Bora for late-stage and commercial mammalian biologics manufacturing, but at substantially larger scale and with broader capabilities.
• WuXi Biologics: Major China-based biologics CDMO with extensive global capacity and integrated discovery-through-commercial services. Competes head-to-head with Bora for mammalian biologics programs, particularly sponsors with Asia-based clinical development seeking a CDMO partner.
• Catalent (Novo Holdings): Large diversified CDMO with biologics drug substance and drug product capabilities, including fill-finish. Competes with Bora on mammalian biologics manufacturing and with affiliate Bora Pharmaceuticals on fill-finish; broader portfolio includes cell and gene therapy.
• Fujifilm Diosynth Biotechnologies: Biologics CDMO with mammalian and microbial development and manufacturing across sites in the U.S., U.K., and Japan. Competes with Bora for late-stage and commercial biologics programs, including biosimilars, with larger footprint and longer-tenured commercial supply relationships.
• Boehringer Ingelheim BioXcellence: Boehringer Ingelheim's biologics CDMO business offering mammalian cell culture and microbial contract manufacturing from clinical through commercial scale. A direct competitor in late-stage and commercial biologics CDMO, with similar end-to-end positioning but substantially larger scale.

Direct peers

• AGC Biologics: Mid-to-large global CDMO offering mammalian and microbial biologics development and manufacturing from clinical through commercial scale. Closely comparable to Bora in scale, mammalian/microbial dual-platform offering, and end-to-end service model, though with broader geographic footprint.
• Cytovance Biologics: U.S.-based CDMO specializing in mammalian and microbial biologics from clinical through commercial scale, including cell line development, process development, and GMP manufacturing. Most directly comparable mid-sized peer to Bora, with similar scale and mammalian/microbial dual-platform focus.

Emerging players

• AbCellera Biologics: Clinical-stage biologics company developing antibody discovery and manufacturing capabilities for partners. Partial overlap with Bora's mammalian biologics development services, but with a stronger discovery-side focus and earlier-stage positioning in the value chain.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bora-biologics

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bora Biologics